A public-disclosable baseline of MZN’s IP and asset portfolio: twelve strategic asset categories plus a reserved foundational theory layer. This page structures the portfolio for Phase 3 diligence through phase boundaries, disclosure layers, maturity-aware review, and strategic-value scenario prompts. It is not the full archive, not a certified valuation, not a transaction price, and not a final legal/IP conclusion.
The numbers shown for each asset are not asking price or transaction terms or transaction terms, and the purpose of this document is not to offer the assets individually for sale. The purpose is to demonstrate the level and class of intellectual-property and asset formation produced during the bounded Phase 2 solo window, and to provide a framework that allows a serious evaluator to review potential strategic value under Phase 3 diligence.
The scenario indications are not arbitrary, and they are not certified. Each asset is presented with a set of evaluation prompts — questions designed so that the reader can walk through the same analytical path that produces the indicated band. The prompts ask the reader to consider, for each asset, whether anyone outside MZN currently holds something comparable, whether those organizations would sell or license what they have, how long and how expensive an internal build would be under realistic conditions, and what the strategic cost is of not having the capability at all.
A class of asset like this is not something most evaluators can value reliably without working through such a framework. The number of people in the world who can independently assess these specific architectures, with full understanding of what they represent, is small. The bands shown are scenario outputs of that analysis — not theatrical figures, not certified valuations, and not final transaction numbers. A qualified evaluator may revise them upward, downward, or remove them after technical, legal/IP, commercial, and buyer-specific diligence.
The work behind this portfolio spans three distinct phases. Each is honest about what it was: a team-built foundation, a bounded solo formation window, and a post-formation institutional stage. Distinguishing them is essential — the solo claim applies to the middle phase only, not retroactively to the prior team work and not forward to the institutional stage now beginning.
A portfolio like this cannot be valued by checking a public price sheet — no public price sheet exists for any of the assets below, because none of them is purchasable in the open market. The framework below is the analytical path that produces defensible scenario review bands for assets of this kind. Each asset is later presented with this same set of questions applied directly to it.
For each asset, apply the six questions below in order. The questions are designed to be answered independently of any claims made by MZN. The reader can verify each step from publicly available information about the relevant industry, the published research, the documented build costs of similar work, and the observable behavior of the organizations that hold comparable internal capability. A disciplined evaluator working through this framework will arrive at a scenario review band that is substantially independent of any number suggested by MZN.
When the six questions above are applied to a given asset, the components — build-cost, time-to-market premium, risk reduction, strategic premium — help structure a scenario review band that is the evaluator-side scenario output of the framework, not a claim made independently of analysis. For each asset in the catalog below, that evaluator-side scenario output is shown alongside the prompts that produced it.
Three assets in this portfolio are presented without a value indication at all, because the framework above cannot be honestly applied to them at this stage. For BioCode, the foundational theoretical layer, the framework cannot be applied because the complete framework has never been presented in public — any value figure would be based on partial information and would mislead in either direction. For HDTP, only the architectural shell and the patent-grade candidates are publicly visible — the operational details that determine market value are reserved. For ISBP within the security portfolio, only the problem identification has been disclosed — the actual solutions, where the value sits, remain undisclosed. For these three, the document acknowledges what is visible and explains why scenario review is reserved.
One additional discipline runs through the entire catalog: every scenario review band shown represents only the public-disclosable layer of the asset. The deeper operational layers — implementation detail, complete candidate claim sets, executable specifications — are reserved for controlled review. The bands shown are therefore an analytical public-layer scenario range, not a final valuation.
The evaluation framework depends on reasonable estimates of build costs, team compositions, and timelines in adjacent categories. The benchmarks below are publicly verifiable reference points that calibrate the analysis. They are not claims about MZN — they are baselines anyone can confirm.
For each asset, the same structure applies: a precise description of what the asset is, the six evaluation prompts with each prompt answered for that specific asset, and the scenario review band that disciplined analysis yields. Assets where the framework cannot yet be honestly applied are shown with the reasoning for why scenario review is reserved.
Each question below can be answered by examining publicly available information about frontier-grade AI organizations and the visible market.
The 21-slot anatomy below maps the structural requirements of a frontier-grade AI organization. For each slot, the current MZN level is marked Strong, Partial, or Gap, based on the public-disclosable evidence. This is an honest signal — not an inflated claim.
MZN is Strong on the foundational architectural layers (model architecture, training, compute security, tokenizer, evaluation core, security operations, privacy governance). Partial on the alignment layers (where multi-team coordination would normally accelerate progress) and on serving infrastructure (where production rollout is deferred to Phase 3). Two Gaps are acknowledged at D4 (customer fine-tuning) and E4 (research infrastructure) — both intentionally outside the solo Phase 2 scope.
The summary below maps public-layer scenario bands for the priced assets and acknowledges the reserved positions. All numbers represent public-disclosable scenario bands only. They are non-additive, buyer-dependent, and subject to Phase 3 diligence.
The “+” symbol marks reserved or undisclosed layers. It should not be read as an invitation to mechanically add values. The priced subtotal represents only public-disclosable scenario bands, while BioCode, HDTP, and reserved ISBP solution layers require qualified review before any responsible value conclusion can be formed.
Across the portfolio, a documented pattern is observable: ideas that appear early in the MZN portfolio — with cryptographic anchoring and blockchain timestamps establishing priority dates — have subsequently appeared in frontier-research directions at multiple major AI laboratories, in some cases with material similarity to the original architectures.
The pattern is presented here as a technical validation signal, not as a legal claim of priority or appropriation. Independent convergence at this rate suggests the formation work was operating in the same problem space as frontier research, often arriving at similar architectural answers months before equivalent public implementations appeared. For an evaluator, the convergence pattern functions as third-party validation that the depth of the work is real — multiple independent research programs at scale have, by their own paths, arrived at adjacent answers.
The specific overlap documentation is available at the asset-detail level under controlled review. The pattern is mentioned here at the directional level only. Cryptographic priority dates are the documentary basis; the appearance of similar concepts in subsequent public research is the validating observation.
None of the signals below were purchased, and none involved a PR firm, an agency, or a paid placement. Each represents an institutional decision made by an external organization, applying its own criteria, on the basis of artifacts submitted personally.
The recognition pattern is meaningful precisely because of how it was generated: by one person, under documented constraints, on the basis of a fraction of the total portfolio (typically two or three modules out of twenty-two presented externally), without PR infrastructure, without institutional channel access, without a Silicon Valley network. The pattern slowly emerges as artifact density becomes too great for the existing recognition system to ignore.
Verification: crunchbase.com/person/mohammad-rahimi-a4e7
The portfolio is built around a layered disclosure model. This document is the public layer — and even within the public layer, the priced assets show only their public-disclosable depth. The deeper layers exist and are referenced; they are not visible here.
Document: MZN-IP-PORTFOLIO-FINAL-2026 · May 22, 2026
Verification chain: SHA-256 hashing across all priority artifacts. Blockchain-timestamped on file. Cross-reference manifests available.
Key reference hashes:
BioCode v1.0 → 50615aea…068505df
Multi-Brain Architecture → 46d9428b…e4f2f937
UIOP Extended → c7698b0c…55884d8f
Output-Centered Safety → a4c5bc69…4c83eb4fa
Patent filing → MZN-PAT-HDTP-2026-0322-001 (12 claims, March 22, 2026)
Contact: partnership@mzncompany.com · mazzaneh.company@gmail.com
I, Mohammad Rahimi, declare that I am the sole creator of the Phase 2 intellectual property described in this portfolio. The solo build phase was carried out using standard AI chat subscriptions, without a team, without collaborators, without API access, without agent frameworks, without automation stacks, and without external code-writing workflows.
Phase 1 outputs were team-built and are explicitly excluded from the one-person claim. Phase 3 has not yet begun and is also explicitly excluded. The 21-slot capability anatomy in this document represents an honest signal of where the portfolio is Strong, Partial, and Gap — not inflated, not reframed, not optimized for evaluator sympathy.
The scenario indications in this document are the output of disciplined analytical work applied to each asset using the framework introduced in the Methodology section. They are not asking price or transaction terms or transaction terms, not transaction targets, and not commitments. They are bands that a serious evaluator working through the same framework would, on average, arrive at independently.
Mohammad Rahimi · Founder, MZN Company · May 22, 2026